I would agree that SGU has better affiliations and in some cases an overall better clinical rotation experience than Touro, as they pay 100 million to rotate at the best hospitals in NYC, although this may change with new legislation being passed to protect NYC med schools.
But that doesn't really matter as far as residency prospects and how well someone fares in the match. SGU is quick to boast things like a 90% USMLE pass rate, 90% match and great rotations, but they don't preface that with the statistic that something like 60-70% of students from Day 1 match within 4 years. So 90% of 60-70% isn't all that impressive IMO. They lose people from attrition, internal tests required to sit for the USMLE, those who repeat a year, do "research" after graduation for 1,2 or 3 years, and overall face a bigger obstacle/stigma in the ACGME match than a DO, without having a separate match to fall back on.
That said, I'm not pro-Touro by any means, more of just anti-Carib the more and more I read about the schools and the expansion of US schools which will make it even harder for FMGs. I think the students who make it out of the Carib are very smart, and just as qualified as anyone else, but they had to overcome a much larger obstacle to get from point A to B than US students, and many in retrospect will acknowledge this and advise applicants to avoid the Carib if possible. I don't know much about Touro, just that it's accredited US institution...
IMO the better question to ask yourself isn't Touro v Ross, it's Touro vs. reapply (if you don't feel comfortable about Touro, that is.)